Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men

被引:353
作者
Nickenig, G
Bäumer, AT
Temur, Y
Kebben, D
Jockenhövel, F
Böhm, M
机构
[1] Univ Cologne, Innere Med Klin 3, D-50924 Cologne, Germany
[2] Univ Cologne, Klin Innere Med 2, D-50924 Cologne, Germany
关键词
lipids; hypertension; angiotensin; receptors; atherosclerosis;
D O I
10.1161/01.CIR.100.21.2131
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Hypercholesterolemia causes an upregulation of vascular angiotensin II type 1 (AT1) receptor expression in cell culture and animal models. The presented studies were undertaken to examine AT1 receptor overexpression in hypercholesterolemic men and therapeutic interventions thereof by HMG CoA reductase inhibitors (statins). Methods and Results-Effects of AT1 receptor activation were measured by assessing the blood pressure increase after infusion of angiotensin II in normo- (cholesterol 181+/-11 mg/dL) and hypercholesterolemic (cholesterol 294+/-10 mg/dL) men (n=19 and 20, respectively). AT1 receptor expression was assessed on isolated platelets. Some patients were investigated before and after cholesterol-lowering therapy with statins. Hypercholesterolemia led to a significant increase of angiotensin II-induced blood pressure elevation. AT1 receptor expression was significantly enhanced in hypercholesterolemic individuals (B-max=5.2+/-1.2 fmol/mg protein) compared with normocholesterolemic men (B-max=2.1+/-0.2 fmol/mg protein). Cholesterol-lowering treatment with statins reversed the elevated blood pressure response to angiotensin II infusion (P<0.05) and downregulated AT1 receptor density (P<0.05). Conclusions-Hypercholesterolemia induces AT1 receptor overexpression and enhances biological effects of angiotensin II in men, These findings provide novel insights into the pathogenesis of hypertension and atherosclerosis and may initiate rational and new therapeutic concepts.
引用
收藏
页码:2131 / 2134
页数:4
相关论文
共 17 条
  • [1] Beisiegel U, 1998, EUR HEART J, V19, pA20
  • [2] INCIDENCE OF CORONARY HEART-DISEASE AND LIPOPROTEIN CHOLESTEROL LEVELS - THE FRAMINGHAM-STUDY
    CASTELLI, WP
    GARRISON, RJ
    WILSON, PWF
    ABBOTT, RD
    KALOUSDIAN, S
    KANNEL, WB
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1986, 256 (20): : 2835 - 2838
  • [3] Nitric oxide, free radicals and cell signalling in cardiovascular disease
    DarleyUsmar, VM
    McAndrew, J
    Patel, R
    Moellering, D
    Lincoln, TM
    Jo, H
    Cornwell, T
    Digerness, S
    White, CR
    [J]. BIOCHEMICAL SOCIETY TRANSACTIONS, 1997, 25 (03) : 925 - 929
  • [4] ANGIOTENSIN-II STIMULATES NADH AND NADPH OXIDASE ACTIVITY IN CULTURED VASCULAR SMOOTH-MUSCLE CELLS
    GRIENDLING, KK
    MINIERI, CA
    OLLERENSHAW, JD
    ALEXANDER, RW
    [J]. CIRCULATION RESEARCH, 1994, 74 (06) : 1141 - 1148
  • [5] MOLECULAR-BIOLOGY OF THE RENIN-ANGIOTENSIN SYSTEM
    GRIENDLING, KK
    MURPHY, TJ
    ALEXANDER, RW
    [J]. CIRCULATION, 1993, 87 (06) : 1816 - 1828
  • [6] Lipoprotein trafficking in vascular cells - Molecular Trojan horses and cellular saboteurs
    Hajjar, DP
    Haberland, ME
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (37) : 22975 - 22978
  • [7] LIPOPROTEINS INCREASE GROWTH OF MITOGEN-STIMULATED ARTERIAL SMOOTH-MUSCLE CELLS
    LIBBY, P
    MIAO, P
    ORDOVAS, JM
    SCHAEFER, EJ
    [J]. JOURNAL OF CELLULAR PHYSIOLOGY, 1985, 124 (01) : 1 - 8
  • [8] Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease - The TREND (Trial on Reversing ENdothelial Dysfunction) study
    Mancini, GBJ
    Henry, GC
    Macaya, C
    ONeill, BJ
    Pucillo, AL
    Carere, RG
    Wargovich, TJ
    Mudra, H
    Luscher, TF
    Klibaner, MI
    Haber, HE
    Uprichard, ACG
    Pepine, CJ
    Pitt, B
    [J]. CIRCULATION, 1996, 94 (03) : 258 - 265
  • [9] MARTIN MJ, 1986, LANCET, V2, P933
  • [10] Nickenig G, 1997, CIRCULATION, V95, P473